Lung cancer drug vizimpro under Real-World watch in korea
NCT ID NCT04721106
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looked at the safety and effectiveness of the drug Vizimpro in 188 adults with advanced lung cancer who had specific gene mutations. It was an observational study, meaning patients received their normal treatment and researchers simply collected data on side effects and tumor response. The goal was to confirm the drug's real-world performance after it was already approved for use in Korea.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL-CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Pfizer
Seoul, South Korea